F2G f2g.com


F2G is advancing F901318, a novel clinical stage candidate for the treatment of invasive aspergillosis – a serious pulmonary infection caused by Aspergillus, a common fungus that affects people with weakened immune systems or lung diseases – and other serious rare mould infections.

F2G is advancing F901318, a novel clinical stage candidate for the treatment of invasive aspergillosis – a serious pulmonary infection caused by Aspergillus, a common fungus that affects people with weakened immune systems or lung diseases – and ...Show all

Company (Alive / Active)

Phone: +44 (0)161 785 1270

Fax:

Lankro Way
Eccles
Manchester, M30 0LX
England, United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
F2G $99.7M Jun 20, 2016

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related F2G Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 11 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Antifungal target Jun 04, 2010 Nov 08, 2016 Patent
Dihydroorotate dehydrogenase as antifungal drug target and quinazolinone-based inhibitors thereof May 01, 2009 May 19, 2015 Patent
Antifungal agents Nov 20, 2015 Application
Pyrrole antifungal agents Feb 18, 2015 Application